We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Blood Test Detects Marker of Metastatic Cancers, Infection and Neurological Disease
News

Blood Test Detects Marker of Metastatic Cancers, Infection and Neurological Disease

Blood Test Detects Marker of Metastatic Cancers, Infection and Neurological Disease
News

Blood Test Detects Marker of Metastatic Cancers, Infection and Neurological Disease

Credit: Karolina Grabowska, Pexels
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Blood Test Detects Marker of Metastatic Cancers, Infection and Neurological Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists at the Walter Reed Army Institute for Research demonstrated the potential of a novel blood test for cathepsin B, a well-studied protein important to brain development and function, as an indicator for a range of disease states.

Cathepsin B plays an important role in the body, regulating the metabolism, immune responses, degradation of improperly produced proteins and other functions. Under certain conditions, such as metastatic cancers, infections, trauma and neurological disease, cathepsin B production is upregulated. Recent research published by WRAIR researchers highlighted the potential of cathepsin B as an indicator, or biomarker, of the severity of traumatic brain injury.

In this study, published in ACS Omega, researchers demonstrated an ultrasensitive assay to measure cathepsin B in blood. While high levels of cathepsin B are readily detectable in aspirates, biopsies and cerebrospinal fluid, a blood test is particularly desirable due to its ease of use with little risk to the patient.

"Although cathepsin can be abundant in some tissues, accurate measurement in blood has been a challenge, especially if changes are expected to be small or sample is limited," said Dr. Bharani Thangavelu, lead author on the paper and researcher at WRAIR's Brain Trauma Neuroprotection Branch. "Our strategy uses an ultrasensitive technique to improve cathepsin B detection from small volumes of blood with little to no noise or impact from interfering substances."

Biomarkers are a source of great interest to researchers due to their potential to dramatically improve both the diagnosis and categorization of disease. Furthermore, they have the potential to validate treatment strategies by indicating whether drugs have reached their proposed targets and achieved therapeutic benefits.

Researchers plan to continue developing and testing the assay, ultimately aiming to develop it into a small, portable diagnostic tool.

"Biomarker tests that accurately reflect the extent and severity of injury can dramatically improve the standard of care, minimizing the need for resource-intensive diagnostics," said Dr. Angela M. Boutté, author and section chief of molecular biology and proteomics within BTN. "This would allow for early, accurate detection as well as monitoring of injury or disease. This aspect is particularly important for assessment of TBI on the battlefield to help guide medical decisions."

Reference: Thangavelu B, Boutté AM. Single molecule assay for ultrasensitive detection of cathepsin b in human blood. ACS Omega. 2021;6(14):9609-9616. doi:10.1021/acsomega.1c00180

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement